Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Histone deacetylase (HDAC) inhibition is a promising anticancer strategy targeting aberrant epigenetic changes.
• The precise mechanisms of HDAC inhibitors (HDACis) in cancer treatment remain under investigation.
• Estrogen receptor (ER)-negative breast cancers often exhibit resistance to hormonal therapy.

Purpose of the Study:

• To evaluate the antitumor activity of a novel synthetic HDAC inhibitor, IN-2001 (3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide).
• To elucidate the molecular mechanisms underlying IN-2001's effects on human breast cancer cell lines.
• To explore potential therapeutic applications of IN-2001, particularly in hormone therapy-resistant breast cancers.

Main Methods:

• Assessed cellular HDAC activity inhibition by IN-2001 in MDA-MB-231 cells.
• Determined the effect of IN-2001 on cell proliferation in ER-negative breast cancer cells.
• Performed cell cycle analysis and examined the modulation of key cell cycle and apoptosis regulatory genes.

Main Results:

• IN-2001 potently inhibited HDAC activity with an IC50 of 0.585 nM in MDA-MB-231 cells.
• IN-2001 demonstrated significant dose-dependent inhibition of cell proliferation in ER-negative breast cancer cells.
• IN-2001 induced cell cycle arrest at G0/G1 and/or G2/M phases, leading to apoptosis and modulating genes like p21(WAF1), p27(KIP1), cyclin D1, and cyclin D2.

Conclusions:

• IN-2001 effectively inhibits proliferation and induces apoptosis in human breast cancer cells.
• The findings suggest IN-2001 as a promising therapeutic agent for human breast cancers.
• Combination therapy with antiestrogens and HDAC inhibitors may offer new approaches for hormone therapy-resistant ER-negative breast cancers.